Anlotinib is a new anti-tumor drug developed independently in China, which can be used to treat advanced non-small cell lung cancer, advanced small cell lung cancer, and a variety of soft tissue sarcomas. Anlotinib is a small molecule multi-target tyrosine kinase inhibitor with dual effects of anti-tumor angiogenesis and inhibition of tumor growth and proliferation. It has been used in clinical practice, and the main indications include: 1. Advanced non-small cell lung cancer: Anlotinib alone can be used for locally advanced or metastatic non-small cell lung cancer that has progressed or recurred after having received at least two previous systemic chemotherapies. For patients with epidermal growth factor receptor gene mutations or positive mesenchymal lymphoma kinase, they should receive the appropriate standard targeted agents prior to treatment; 2. Advanced small cell lung cancer: Anlotinib alone can also be used for advanced small cell lung cancer that has progressed or relapsed after receiving at least two prior chemotherapy regimens; 3. Soft tissue sarcoma: Anlotinib alone can also be used for adenoidal soft tissue sarcoma, clear cell sarcoma, and other advanced soft tissue sarcomas that have progressed or recurred after at least one prior anthracycline-containing chemotherapy regimen, for some ovarian cancers, breast cancers, biliary tumors, esophageal cancers, head and neck tumors, etc. In addition to the above common indications for Anrotinib, Anrotinib can also be used in combination with other drugs, such as chemotherapy drugs or targeted drugs, in medullary thyroid cancer and metastatic renal cell carcinoma, which can also achieve certain efficacy and can play a better synergistic treatment role.